← Back to Clinical Trials
Recruiting NCT07083089

NCT07083089 Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07083089
Status Recruiting
Phase
Sponsor Cilcare SAS
Condition Mild Cognitive Impairment (MCI) Amnestic
Study Type INTERVENTIONAL
Enrollment 309 participants
Start Date 2025-03-24
Primary Completion 2026-12

Trial Parameters

Condition Mild Cognitive Impairment (MCI) Amnestic
Sponsor Cilcare SAS
Study Type INTERVENTIONAL
Phase N/A
Enrollment 309
Sex ALL
Min Age 50 Years
Max Age 85 Years
Start Date 2025-03-24
Completion 2026-12
Interventions
Thorough Hearing assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The study aims to phenotype hearing in patients with early stage of neurodegenerative disorders to explore the prevalence of various hearing disorders in comparison to a control population. Specific focus is made on patients with speech-in-noise intelligibiltiy deficit despite normal tonal audiograms referred to as hidden hearing loss, with potential identification of associated biomarkers.

Eligibility Criteria

Inclusion Criteria: All subjects 1. Man or woman aged between 50 and 85 years old at baseline. 2. Fluent in French (native language) 3. Be considered as reliable and capable of adhering to the protocol, according to the judgment of the investigator (understanding of the information included in the protocol, and requests to realize the investigations, good general health and able to move around). 4. Affiliated to Public Health Insurance (Sécurité Sociale) 5. Signed and dated informed consent form. For amnestic MCI: Diagnosis of amnestic MCI, according to international diagnosis criteria (NIA-AA, 2011) with MoCA≥23 or MMSE\>24.Patients must exhibit predominantly cognitive impairments in episodic memory, defined by a score on the RL/RI 16-item test with a free recall score of less than 18/48 and a total recall score of less than 40/48. For Parkinson Patients: Established clinical diagnosis of Parkinson's disease according to Postuma et al. 2015 with bradykinesia associated with resting tr

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology